A review of one research paper.

Our review questions

Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study

Study review

Editorial draft

Prepared by AI-assisted editorial draft; independent review pending

Not independently approved.

Review version 2026-10-11-iv-draft-1

Paper published: 2025

Study at a glance

Design
Uncontrolled, two-participant safety pilot
Who or what was studied
Two adults aged 58 and 68 who had previously received intravenous BPC-157

Neither participant reported side effects during two infusion days and follow-up through the next day.

Key limitation: Two previously exposed adults followed for three days cannot establish general, rare-event or long-term safety, and the study did not test injury recovery.

Preview sources: PDF pages 1; PDF pages 2; PDF pages 3; PDF pages 4; PDF pages 5

This is an AI-assisted editorial draft. Unresolved questions and source checks are identified in the review; it has not received independent methodological or clinical approval.

Log in to read the full review

Read the methods, numerical findings, harms, limitations, and source locations with a free PepsAnon account.

Log in to continue

No subscription or payment is required.